1. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (1st June 2020) Authors: Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.; Vender, Ronald; Lomaga, Mark A.; Delorme, Isabelle Journal: British journal of dermatology Issue: Volume 182:Number 6(2020) Page Start: 1348 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. (2nd December 2017) Authors: Al Sawah, Sarah; Foster, Shonda A.; Burge, Russel; Amato, David; Schacht, Alexander; Zhu, Baojin; Hartz, Susanne; Leonardi, Craig Journal: Journal of medical economics Issue: Volume 20:Number 12(2017) Page Start: 1224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Healthcare Resource Utilization and Baseline Characteristics of Patients With Generalized Pustular Psoriasis: Real-World Results From a Large US Database of Multiple Commercial Medical Insurers. Issue 3 (July 2021) Authors: Sobell, Jeffrey M.; Gao, Ran; Golembesky, Amanda K.; Kotowsky, Nirali; Garry, Elizabeth M.; Comerford, Erin O.; Bohn, Rhonda L.; Valdecantos, Wendell C.; Feldman, Steven R.; Leonardi, Craig Journal: Journal of psoriasis and psoriatic arthritis Issue: Volume 6:Issue 3(2021) Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice. (19th May 2022) Authors: Leonardi, Craig; Tao, Rei; Setayeshgar, Solmaz; Wang, Sisi; Burge, Russel; Zhu, Baojin; Malatestinic, William N. Journal: Journal of dermatological treatment Issue: Volume 33:Number 4(2022) Page Start: 2278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). (19th May 2017) Authors: Reich, Kristian; Leonardi, Craig; Lebwohl, Mark; Kerdel, Francisco; Okubo, Yukari; Romiti, Ricardo; Goldblum, Orin; Dennehy, Ellen B.; Kerr, Lisa; Sofen, Howard Journal: Journal of dermatological treatment Issue: Volume 28:Number 4(2017) Page Start: 282 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Three‐year U.S. pharmacovigilance report of brodalumab. Issue 6 (5th September 2021) Authors: Lebwohl, Mark; Leonardi, Craig; Armstrong, April; Rawnsley, Nicole; Alexander, Binu; Goehring, Earl; Kerdel, Francisco; Jacobson, Abby Journal: Dermatologic therapy Issue: Volume 34:Issue 6(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. Issue 2 (April 2021) Authors: Muzumdar, Sonal; Leonardi, Craig; Strober, Bruce Journal: Journal of psoriasis and psoriatic arthritis Issue: Volume 6:Issue 2(2021) Page Start: 93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗